MedTrace Logo

Effect of Vitamin D on Inflammatory Markers in Type 2 Diabetes Mellitus in Mexico.

NCT06993064 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-29

No results posted yet for this study

Summary

Type 2 Diabetes Mellitus (T2DM) is a very common disease in Mexico, and its long-term complications affect years of healthy life and a high cost in treatmenty. T2DM is a chronic disease associated to inflammation. We aim to establish if Vitamin D may help decrease this inflammation and improve the condition in adults with T2DM. Patients included in the study will have to take 1 pill/day of vitamin D for six months. The investigators will measure weight, height, waist and hip circumference, systolic and dyastolic blood pressure; obtain dietary and clinical information, as well as a 10mL blood sample from the arm, for laboratory analyses, finger-prick blood sample for glucose at the beginning and end of the study; ´plus a finger-prick blood samplo for the initial vitamin D status. The study is completely free for the participants and they may withdraw their consent at any time without any consequences. Participants will have to attend the clinic at the beginning and every two months until the end, to receive their supplement (total 4 appointments). They will receive a phone call once a week to remind you to take your pills. They will be handed your results at the end of the study.

Conditions

  • Type 2 Diabetes Melitus
  • Inflammation Biomarkers

Interventions

DIETARY_SUPPLEMENT

4000 IU of Vitamin D3

Vitamin D supplementation in Mexican subjects with Type 2 Diabetes Mellitus

Sponsors & Collaborators

  • Universidad Autonoma del Estado de Mexico

    lead OTHER

Principal Investigators

  • Mariana Ortíz Reynoso, DPharm · Secretary of Research and Graduate Studies. Universidad Autónoma del Estado de México.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-06-27
Completion
2026-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06993064 on ClinicalTrials.gov